Please login to the form below

Not currently logged in
Email:
Password:

AZ appoints Pam Cheng as executive VP, operations and IT

She joins from MSD China where she was president

edit-AZ-Pam-ChengAstraZeneca has named Pam Cheng as executive vice president, operations and IT.

Cheng succeeds David Smith, who is retiring after nearly ten years at the firm. She will be responsible for manufacturing operations and supply chain, procurement and information technology globally.

In the role, she will oversee AZ's progression in driving efficiency and delivering excellence within her field.

Pascal Soriot, CEO at AZ, commented: “I am delighted to welcome Pam to AstraZeneca at a very exciting time for our business. As our pipeline delivers, we will bring an increasing number of new medicines to patients across the globe over the coming years, including important biological therapies as our product mix shifts. 

“Pam will be able to bring to bear her wealth of experience in manufacturing and supply chain management, as well as her experience in emerging markets, particularly China, a key priority for our company.”

Cheng joins from Merck/MSD, where she was most recently chief operating officer and then president of MSD China.

At the company, Cheng gained extensive experience in pharma manufacturing and supply chain management as director of global planning and capacity management and head of global supply chain management and logistics. 

19th June 2015

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics